[144] Surgery Partners, Inc. SEC Filing

Rhea-AI Filing Summary

Surgery Partners, Inc. (SGRY) Form 144 notice reports a proposed sale of 25,000 common shares through UBS Financial Services on NASDAQ, with an aggregate market value of $560,250 and approximately 128,209,410 shares outstanding. The filing shows the shares were acquired and exercised as equity compensation on 09/03/2025 and are scheduled for sale the same day via an equity option exercise. The filer also disclosed four recent sales by the same person totaling 161,865 shares with gross proceeds shown for each transaction. The notice includes the filer’s certification that no undisclosed material adverse information is known.

Insights

Securities Analyst

TL;DR: Routine insider sale of option-exercised shares, disclosed under Rule 144; aggregate recent sales are small relative to outstanding shares.

The filing documents a proposed sale of 25,000 common shares acquired via equity compensation and exercised on 09/03/2025, to be brokered by UBS on NASDAQ for $560,250. Prior sales by the same individual total 161,865 shares over recent dates with listed gross proceeds. Compared with the reported 128.2 million shares outstanding, these transactions represent a de minimis percentage and are likely non-material to equity valuation. Disclosure appears complete for Rule 144 purposes.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; signer affirms no undisclosed material adverse information.

The notice provides required information on the source of the shares (equity compensation and option exercise), broker details, and recent sales history for the reporting person. The signature statement affirms absence of undisclosed material adverse information and references trading-plan representation. There is no indication in this filing of governance issues or material insider events beyond routine monetization of equity awards.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	25000	560250	128209410	09/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	09/03/2025	equity compensation	Surgery Partners, Inc.			25000	09/03/2025	Equity option exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/21/2025	100000	2299011
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/26/2025	25000	572717
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/27/2025	11865	271756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/02/2025	25000	562150

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for SGRY report?

The Form 144 reports a proposed sale of 25,000 common shares acquired via equity compensation and exercised on 09/03/2025, listed with UBS for sale on NASDAQ.

How many shares outstanding does Surgery Partners report in the filing?

The filing lists approximately 128,209,410 shares outstanding.

What recent sales by the reporting person are disclosed?

The filing discloses four recent sales totaling 161,865 shares on 08/21/2025, 08/26/2025, 08/27/2025, and 09/02/2025 with gross proceeds shown for each transaction.

How much aggregate market value is listed for the proposed 25,000-share sale?

The aggregate market value reported for the 25,000 shares is $560,250.

Who is the broker named in the Form 144?

The broker named is UBS Financial Services Inc, 1000 Harbor Blvd, 3rd Floor, Weehawken, NJ.